Insulet posts third quarter results
BEDFORD, Mass. – Insulet’s revenues reached $61.1 million in the third quarter compared to $54.8 million during the same period last year, a 12% increase, the company announced Nov. 7. The medical device company’s gross profit for the period was $27.4 million, also a 12% increase. Insulet’s revenues in the first nine months of the year were $178.6 million vs. $153.5 million for the same period last year, while gross profit was $79.4 million vs. $67 million. Increased operating expenses were due to the settlement of a patent-infringement dispute with Medtronic involving Insulet’s OmniPod.